Sias Raises Concerns Over Accrelist's Financial Discrepancies Following Audit Adjustments

Singapore, Singapore Jul 24, 2026 ALN: [SINGAPORE] The Securities Investors Association (Singapore), or Sias, has raised significant concerns regarding Accrelist, a medical aesthetics firm, following a series of financial discrepancies that have come to light after recent audit adjustments. These discrepancies have prompted Sias to request clarification from Accrelist about the reasons behind the repeated material variances between its unaudited and audited financial statements.

This scrutiny comes in the wake of audit adjustments made by the Catalist-listed company on July 13, which drastically revised its financial results for the fiscal year 2026 (FY2026). The adjustments revealed that Accrelist's net loss had increased more than fourfold, soaring to S$264,000 from a previously reported S$1.14 million. In addition to this alarming increase in losses, the equity attributable to equity holders also saw a notable decline of approximately 10 percent, falling to S$8.2 million.

Sias highlighted a troubling trend in Accrelist’s financial reporting, noting that the company has reported material variances between its unaudited and audited financial statements in nine out of the last ten financial years, with the exception of FY2019. This pattern raises questions about the reliability of the financial data being presented to investors and stakeholders, as consistent discrepancies can undermine confidence in a company's financial health. Investors rely heavily on accurate financial reporting to make informed decisions, and discrepancies can lead to a loss of trust, which may have long-term implications for the company's market position and share price.

In response to these concerns, Accrelist issued a statement ahead of its annual general meeting scheduled for July 29. The company attributed the recurring discrepancies to "delays or adjustments arising at the subsidiary level, including at overseas entities," which ultimately affect the accuracy of the group’s consolidated results. This explanation points to potential issues in the financial reporting processes at the subsidiary level, suggesting that the complexities of managing international operations may be contributing to the inconsistencies in financial reporting. Such challenges are not uncommon for companies operating in multiple jurisdictions, where different regulatory environments and accounting practices can complicate the consolidation of financial statements.

To mitigate these issues, Accrelist announced that it has taken steps to strengthen its finance function. The company indicated that it has provided additional resources to the team responsible for year-end reporting, aiming to enhance the accuracy and reliability of its financial statements. Furthermore, Accrelist emphasized its commitment to resolving any issues that arise between auditors and the subsidiaries’ accountants promptly. The company stated that contentious issues are brought to the audit committee’s attention early in the process, which is intended to facilitate quicker resolutions and improve the overall financial reporting framework. This proactive approach is essential for restoring investor confidence, as it demonstrates a commitment to transparency and accountability in financial reporting.

In addition to addressing the audit discrepancies, Accrelist responded to Sias's inquiries regarding accounting reclassifications within its core medical aesthetics segment. The company also discussed the recent appointment of a new chief executive officer, who comes from the food and beverage sector. This leadership change may signal a strategic shift for Accrelist as it seeks to leverage new expertise to navigate the challenges within the medical aesthetics industry. The appointment of a CEO with a diverse background could bring fresh perspectives and innovative strategies to the company, which may be critical as it seeks to enhance its competitive edge in a rapidly evolving market.

Despite the financial setbacks highlighted by the audit adjustments, Sias noted that there were some positive developments within Accrelist's business operations. For FY2026, the group’s aesthetics medical services (AMS) segment reported an improvement in its gross profit margin, increasing from 38 to 44 percent. This uptick in profitability is a positive sign, indicating that the company is making strides in enhancing its service offerings and operational efficiency. The improvement in gross profit margin could also reflect successful cost management initiatives or increased demand for the company's services, which may be crucial for sustaining growth in the competitive medical aesthetics market.

However, the report also revealed that while marketing and distribution expenses saw a decline of approximately S$200,000, administrative expenses rose significantly, increasing by about S$2.5 million. This rise in administrative costs has more than offset the improvements in gross profit, indicating that the company may need to reassess its cost management strategies. Accrelist noted that the administrative expenses primarily consisted of depreciation of property, plant, and equipment, while employee compensation remained relatively stable at S$5 million in FY2026, revised down from an earlier estimate of approximately S$7.5 million. This revision was attributed to a reclassification between segments, which underscores the complexities involved in financial reporting. The increase in administrative expenses could also signal potential inefficiencies that need to be addressed to improve overall profitability.

As a result of these financial dynamics, the AMS segment recorded a profit before income tax of S$1.2 million in FY2026, marking a significant turnaround from the loss before income tax of S$1.1 million reported in FY2025. This improvement suggests that while Accrelist is facing challenges in its overall financial reporting, certain segments of the business are performing better, which may provide a foundation for future growth. The positive performance of the AMS segment could serve as a critical pillar for the company as it seeks to navigate through its financial challenges and regain investor confidence.

Looking ahead, Accrelist has expressed its intention to continue monitoring its cost base as it seeks to expand the AMS segment. This focus on cost management will be critical as the company navigates the complexities of the medical aesthetics market and strives to improve its financial performance. The ability to control costs while enhancing service offerings will be a key determinant of Accrelist's success in the coming years, especially in light of the scrutiny from investors and regulatory bodies. As the company implements its strategies, it will be essential for Accrelist to maintain open lines of communication with its stakeholders, ensuring that they are informed of progress and any potential challenges that arise.

In summary, the concerns raised by Sias regarding Accrelist's financial discrepancies highlight the importance of transparency and accuracy in financial reporting. As the company works to address these issues and improve its financial processes, stakeholders will be closely watching to see how these changes impact its overall performance and investor confidence in the future. The scrutiny from Sias serves as a reminder to all publicly listed companies about the critical nature of reliable financial reporting and the potential repercussions of discrepancies in the eyes of investors and regulators alike. As Accrelist moves forward, it will be crucial for the company to not only rectify its current issues but also to establish a robust framework for financial reporting that can withstand future challenges.